Introduction {#s1}
============

Small cell lung cancer (SCLC) is an important type of lung cancer and accounts for \~13% of all lung cancer ([@B1]). SCLC is notorious for its aggressive behavior, and most SCLC is initially diagnosed as extensive-stage disease. Chemotherapy and radiotherapy are currently the predominant treatment modalities for SCLC due to its chemoradiosensitivity. The prognosis of SCLC patients is bleak with a 5-year survival rate of only 6% ([@B2], [@B3]). However, a certain number of SCLC patients become long-term survivors after radiotherapy and chemotherapy. Previous studies have demonstrated that these patients are at high risk for developing a second primary malignancy, including non-small cell lung cancer (NSCLC), possibly related to the secondary effect of chemoradiation ([@B4], [@B5]). In addition, It is well-established that different histology is one of the most robust criteria for the diagnosis of second primary lung cancer, which are endorsed by both International Association for the Study of Lung Cancer (IASLC) TNM staging proposal and American College of Chest Physicians (ACCP) guideline ([@B6], [@B7]). Therefore, it is reasonable to consider NSCLC diagnosed after SCLC as second primary lung cancer because these two cancers are different in histology.

Currently, no clinical guideline or consensus has addressed the optimal treatment strategy for early-stage second primary non-small cell lung cancer (SPLC) after SCLC. In addition, to the best of our knowledge, no previous study has evaluated the survival benefits of surgical resection for these patients.

In this study, we searched the Surveillance, Epidemiology, and End Results (SEER) database to analyze the characteristics of early-stage SPLC after SCLC, and we aimed to evaluate the survival benefits of surgery for these patients.

Materials and Methods {#s2}
=====================

Study Population and Outcomes
-----------------------------

Patients with early-stage SPLC after SCLC were identified from the SEER Multiple Primary Standardized Incidence Ratios (MP-SIR) session (April 2019 released, 2000--2016). A minimal interval of 6 months was required between initial SCLC and SPLC, considering the general treatment and surveillance protocol of SCLC.

Patients\' clinicopathological characteristics, treatment information, and survival outcomes were also extracted from SEER. Tumor histology was classified with the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) morphology codes according to the 2015 World Health Organization Classification of Lung Tumors ([@B8]). Specific inclusion criteria were listed as follows: (1) ICD-O-3 topographical codes: C340--C349 (lung and bronchus); (2) ICD-0-3 histology codes of the first primary lung cancer: 8002, 8041--8045 (small cell lung cancer); (3) age at diagnosis of SCLC: no less than 18 years old; (4) time of diagnosis of SPLC: 2000.1--2014.12. On the other hand, specific exclusion criteria were listed as follows: (1) ICD-O-3 histology site of the second primary lung cancer: 8002, 8041--8045 (small cell lung cancer as SPLC was excluded); (2) interval between the two cancers was less than 6 months; (3) cause of death or TNM staging information unknown; (4) N2/3 station lymph node involvement or distant metastasis. Surgery on SPLC included sublobar resection (wedge resection, segmentectomy, or other unspecified resections of less than one lobe), lobectomy, bilobectomy, pneumonectomy, and other non-specified local resection. Therefore, all selected SPLC patients with SEER Site-Specific Surgery of Primary Site Code between 10 and 90 were classified as surgery group, while Code 00 and 99 were classified as non-surgery group.

The primary and secondary outcomes in this study were overall survival (OS) and lung cancer-specific survival (CSS), respectively. The survival time was calculated from the time of SPLC diagnosis to the time of death or the last follow-up in months. All patients were followed up to December 31, 2016; patients who were alive at the last follow-up were censored. In addition, causes of death other than lung cancer were also censored in the CSS analysis.

Statistical Analysis
--------------------

The differences between the non-surgery group and the surgery group were compared by Pearson chi-square tests or Fisher\'s exact tests. Multiple comparisons were adjusted by the Bonferroni correction. The Kaplan--Meier method and log-rank tests were applied in survival analysis. Potential statistically significant factors (*P* \< 0.10) identified from the univariate survival analysis were further selected into the Cox proportional hazards regression model for the multivariate survival analysis and subgroup analysis. The Cox regression model was developed by forward stepwise selection (likelihood-ratio) with entry and removal probabilities of 0.05 and 0.10, respectively. For the subgroup analysis, variables deemed clinically significant or those that demonstrated a survival difference in the previous multivariate Cox regression were included. Surgery for SPLC served as the comparing factor while the other included variables served as subgroup variables in turn.

Propensity score matching (PSM) was performed between the non-surgery group and the surgery group to reduce potential bias in this retrospective study. Variables deemed clinically significant and variables significantly different between the non-surgery group and the surgery group were selected as the predictor covariates in PSM. The match tolerance (caliper) was set at 0.02 and 1:1 nearest neighbor matching was performed. In this study, PSM sampled without replacement and implemented logistic regression ([@B9]).

All statistical analysis and PSM were conducted with IBM SPSS Statistics Version 25, and the survival curves and forest plot were drawn by R version 3.6.1. A two-sided *P-*value \< 0.05 was considered statistically significant.

Results {#s3}
=======

A total of 228 early-stage SPLC after SCLC patients were identified according to the selection criteria, among which 105 received surgery while 123 did not (selection flow, [Figure 1](#F1){ref-type="fig"}). For the surgery group, the interval between the two cancers and the median follow-up time were 37 and 36 months, respectively; as for the non-surgery group, the interval between the two cancers and the median follow-up time were 47 and 21 months, respectively.

![Selection flow: (a) SEER MP-SIR: Surveillance, Epidemiology, and End Results (SEER) Multiple Primary Standardized Incidence Ratios (MP-SIR) session specializes in conducting an analysis examining multiple subsequent cancers. (b) SPLC: second primary non-small cell lung cancer after small cell lung cancer. (c) SCLC: small cell lung cancer.](fonc-09-01552-g0001){#F1}

The pertinent clinicopathological factors were compared between the non-surgery group and the surgery group, and patients who underwent surgery were more likely to be younger and married. The surgery group was associated with limited stage SCLC, SPLC of smaller tumor size, and shorter interval between cancers. On the other hand, the histology and differentiation grade in the non-surgery group were more likely to be unclassified. Moreover, patients in the non-surgery group were more likely to receive chemotherapy and radiotherapy for SPLC. However, proportions of previous chemotherapy and radiotherapy for the initial SCLC were not significantly different between the two groups ([Table 1](#T1){ref-type="table"}).

###### 

Comparison of clinicopathological factors between the non-surgery group and surgery group.

                                                                                                                                                                 **Non-surgery group**   **Surgery group**   ***P***           
  ------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ----------------------- ------------------- --------- ------- --------
  Age                                                                                                                 ≤70 years old                              63                      51.2%               71        67.6%   0.01
                                                                                                                      \>70 years old                             60                      48.8%               34        32.4%   
  Gender                                                                                                              Female                                     71                      57.7%               58        55.2%   0.71
                                                                                                                      Male                                       52                      42.3%               47        44.8%   
  Ethnicity[^@^](#TN3){ref-type="table-fn"}^,^[^\*^](#TN4){ref-type="table-fn"}                                       Caucasian                                  108                     87.8%               96        91.4%   0.54
                                                                                                                      African American                           12                      9.8%                6         5.7%    
                                                                                                                      Others                                     3                       2.4%                3         2.9%    
  Marital status at SPLC[^a^](#TN1){ref-type="table-fn"}                                                              Married                                    52                      42.3%               64        61.0%   0.01
                                                                                                                      Not married                                71                      57.7%               41        39.0%   
  Interval between SPLC and SCLC[^b^](#TN2){ref-type="table-fn"}                                                      ≤48 months                                 65                      52.8%               69        65.7%   0.05
                                                                                                                      \>48 months                                58                      47.2%               36        34.3%   
  SPLC laterality                                                                                                     Left                                       54                      43.9%               45        42.9%   0.87
                                                                                                                      Right                                      69                      56.1%               60        57.1%   
  Laterality relationship between SPLC and SCLC[^@^](#TN3){ref-type="table-fn"}^,^[^\*^](#TN4){ref-type="table-fn"}   Same                                       57                      46.3%               47        44.8%   0.97
                                                                                                                      Different                                  62                      50.4%               55        52.4%   
                                                                                                                      NA                                         4                       3.3%                3         2.9%    
  SPLC primary site[^@^](#TN3){ref-type="table-fn"}^,^[^\*^](#TN4){ref-type="table-fn"}                               Upper lobe                                 86                      69.9%               61        58.1%   0.24
                                                                                                                      Middle lobe                                3                       2.4%                6         5.7%    
                                                                                                                      Lower lobe                                 32                      26.0%               35        33.3%   
                                                                                                                      Main bronchus/Overlapping lesion/Unknown   2                       1.6%                3         2.9%    
  SCLC primary site[^@^](#TN3){ref-type="table-fn"}^,^[^\*^](#TN4){ref-type="table-fn"}                               Upper lobe                                 72                      58.5%               61        58.1%   0.83
                                                                                                                      Middle lobe                                3                       2.4%                3         2.9%    
                                                                                                                      Lower lobe                                 21                      17.1%               22        21.0%   
                                                                                                                      Main bronchus/Overlapping lesion/Unknown   27                      22.0%               19        18.1%   
  SPLC tumor size                                                                                                     ≤2 cm                                      57                      46.3%               65        61.9%   0.02
                                                                                                                      \>2 cm                                     66                      53.7%               40        38.1%   
  Lymph node involvement                                                                                              No                                         114                     92.7%               99        94.3%   0.63
                                                                                                                      Yes                                        9                       7.3%                6         5.7%    
  SPLC stage                                                                                                          IA--IB                                     95                      77.2%               91        86.7%   0.07
                                                                                                                      IIA--IIIA                                  28                      22.8%               14        13.3%   
  SPLC histology                                                                                                      Adenocarcinoma                             36                      29.3%               39        37.1%   0.04
                                                                                                                      Squamous cell carcinoma                    54                      43.9%               52        49.5%   
                                                                                                                      Others                                     33                      26.8%               14        13.3%   
  SPLC differentiation grade[^\*^](#TN4){ref-type="table-fn"}                                                         Well/moderately differentiated             23                      18.7%               58        55.2%   \<0.01
                                                                                                                      Poorly differentiated/undifferentiated     33                      26.8%               37        35.2%   
                                                                                                                      unknown                                    67                      54.5%               10        9.5%    
  SPLC chemotherapy                                                                                                   No                                         88                      71.5%               91        86.7%   \<0.01
                                                                                                                      Yes                                        35                      28.5%               14        13.3%   
  SPLC radiotherapy                                                                                                   No                                         41                      33.3%               98        93.3%   \<0.01
                                                                                                                      Yes                                        82                      66.7%               7         6.7%    
  SCLC stage                                                                                                          Limited stage                              92                      74.8%               94        89.5%   \<0.01
                                                                                                                      Extensive stage                            31                      25.2%               11        10.5%   
  SCLC surgery                                                                                                        No                                         106                     86.2%               88        83.8%   0.62
                                                                                                                      Yes                                        17                      13.8%               17        16.2%   
  SCLC chemotherapy                                                                                                   No                                         15                      12.2%               13        12.4%   0.97
                                                                                                                      Yes                                        108                     87.8%               92        87.6%   
  SCLC radiotherapy                                                                                                   No                                         34                      27.6%               25        23.8%   0.51
                                                                                                                      Yes                                        89                      72.4%               80        76.2%   

SPLC, second primary non-small cell lung cancer after small cell lung cancer;

SCLC, small cell lung cancer;

At least one of the cells had expected cell count \<5, Fisher\'s exact test was used;

*Multiple comparisons were adjusted by Bonferroni correction*.

In the univariate survival analysis, patients with SPLC ≤ 2 cm, without N1 lymph node involvement, and who underwent surgery for SPLC were associated with both better OS and CSS. Surgery for SCLC demonstrated survival benefit in OS but not in CSS. Meanwhile, unclassified SPLC histology and differentiation grades were associated with worse OS and CSS. As for multivariate Cox regression, surgery for SPLC was associated with significantly improved survival (OS, 5-year rate: 41.2 vs. 11.6%, HR: 0.42, 95% CI: 0.31--0.59, *P* \< 0.01; CSS, 5-year rate: 46.8 vs. 24.3%, HR: 0.53, 95% CI: 0.37--0.75, *P* \< 0.01). In addition, a longer interval between cancers, SPLC ≤ 2 cm, SPLC without N1 lymph node involvement, and surgery for SCLC were also associated with significantly longer survival ([Table 2](#T2){ref-type="table"}).

###### 

Univariate and multivariate Cox regression of early-stage SPLC after SCLC.

  **Variables[^a^](#TN5){ref-type="table-fn"}**                                              **Univariate analysis**   **Multivariate analysis**                                                                                          
  ----------------------------------------------- ------------------------------------------ ------------------------- --------------------------- -------- ------------------- -------- ------------------- -------- ------------------- --------
  Age                                             ≤70 years old                              134                                                   0.97                         0.25                         0.87                         0.31
                                                  \>70 years old                             94                                                                                                                                           
  Gender                                          Female                                     129                                                   0.13                         0.10                         0.23                         0.11
                                                  Male                                       99                                                                                                                                           
  Ethnicity                                       Caucasian                                  204                                                   0.75                         0.79                                                      
                                                  African American                           18                                                    0.48                         0.50                                                      
                                                  Others                                     6                                                     0.77                         0.90                                                      
  Interval between cancers                        ≤48 months                                 134                                                   0.36                         0.07     Reference           0.04     Reference           \<0.01
                                                  \>48 months                                94                                                                                          0.71 (0.52--0.99)            0.61 (0.42--0.88)   
  Marital status                                  Married                                    116                                                   0.93                         0.8                                                       
                                                  Not married                                112                                                                                                                                          
  Laterality                                      Left                                       99                                                    0.12                         0.41                                                      
                                                  Right                                      129                                                                                                                                          
  Primary site                                    Upper lobe                                 147                                                   0.73                         0.91                                                      
                                                  Middle lobe                                9                                                     0.99                         0.65                                                      
                                                  Lower lobe                                 67                                                    0.4                          0.64                                                      
                                                  Main bronchus/Overlapping lesion/Unknown   5                                                     0.5                          0.83                                                      
  Tumor size                                      ≤2 cm                                      122                       Reference                   \<0.01   Reference           \<0.01   Reference           0.01     Reference           \<0.01
                                                  \>2 cm                                     106                       1.59 (1.18--2.16)                    1.67 (1.19--2.35)            1.49 (1.10--2.03)            1.65 (1.17--2.33)   
  Lymph node involvement                          No                                         213                       Reference                   \<0.01   Reference           0.02     Reference           \<0.01   Reference           \<0.01
                                                  Yes                                        15                        2.81 (1.58--5.01)                    2.35 (1.18--4.67)            2.93 (1.64--5.24)            2.50 (1.25--5.01)   
  Histology                                       Adenocarcinoma                             75                        Reference                   0.05                         0.09                         0.13                         0.22
                                                  Squamous cell carcinoma                    106                       1.13 (0.79--1.61)           0.51                         0.47                         0.61                         0.60
                                                  Others                                     47                        1.66 (1.10--2.52)           0.02                         0.03                         0.05                         0.09
  Differentiation grade                           Well/moderately differentiated             81                        Reference                   0.03     Reference           0.01                         0.88                         0.33
                                                  Poorly differentiated/ undifferentiated    70                        1.22 (0.84--1.78)           0.31     1.63 (1.06--2.50)   0.03                         0.66                         0.23
                                                  Unknown                                    77                        1.63 (1.13--2.35)           0.01     1.83 (1.19--2.81)   0.01                         0.98                         0.94
  SPLC surgery                                    No                                         123                       Reference                   \<0.01   Reference           \<0.01   Reference           \<0.01   Reference           \<0.01
                                                  Yes                                        105                       0.44 (0.32--0.61)                    0.54 (0.38--0.77)            0.42 (0.31--0.59)            0.53 (0.37--0.75)   
  SCLC[^b^](#TN6){ref-type="table-fn"} stage      Limited stage                              186                                                   0.33                         0.86                                                      
                                                  Extensive stage                            42                                                                                                                                           
  SCLC surgery                                    No                                         194                       Reference                   0.03                         0.06     Reference           0.05                         0.10
                                                  Yes                                        34                        0.58 (0.36--0.93)                                                 0.61 (0.38--0.99)                                
  SCLC chemotherapy                               No                                         28                                                    0.06                         0.13                                                      
                                                  Yes                                        200                                                                                                                                          
  SCLC radiotherapy                               No                                         59                                                    0.09     Reference           0.03                                                      
                                                  Yes                                        169                                                            1.59 (1.05--2.42)                                                             

Variables of non-small cell lung cancer if not otherwise specified;

*SCLC, small cell lung cancer*.

Subgroup analysis by age, gender, interval between cancers, SPLC tumor size, SPLC differentiation grade, SCLC stage, SCLC surgery, SCLC chemotherapy, and SCLC radiotherapy demonstrated that surgery for SPLC was associated with improved survivals for most subgroups (forest plot, [Figure 2](#F2){ref-type="fig"}).

![Subgroup analysis by age, gender, interval between cancers, SPLC tumor size, SPLC differentiation grade, SCLC stage, SCLC surgery, SCLC chemotherapy, and SCLC radiotherapy. (a) SPLC: second primary non-small cell lung cancer after SCLC. (b) SCLC: small cell lung cancer.](fonc-09-01552-g0002){#F2}

Among the 105 patients in the surgery group, 43.8% underwent sublobar resection and 51.4% underwent lobectomy, and no statistically significant survival difference was found between sublobar resection and lobectomy (OS, 5-year survival: 41.0 vs. 45.3%, *P* = 0.73; CSS, 5-year survival: 43.5 vs. 54.1%, *P* = 0.49). Regarding the lymph node evaluation during surgery for SPLC, the median number of evaluated lymph node during surgery was 2 and 69.5% patients had at least one lymph node examined during surgery. However, there is no statistically significant survival difference between patients with and without surgical lymph node evaluation (OS, 5-year survival: 30.3 vs. 45.8%, *P* = 0.38; CSS: 5-year survival: 33.1 vs. 52.6%, *P* = 0.29).

Predictor covariates used in PSM included age, gender, marital status, tumor size, lymph node involvement, surgery for SCLC, and interval between cancers. It should be noted that SPLC chemotherapy or radiotherapy was not chosen as predictor covariate in PSM, because they had strong correlation with SPLC surgery and might cause multicollinearity problem. After 1:1 PSM, 162 patients were selected for further analysis (selection flow, [Figure 1](#F1){ref-type="fig"}). No statistically significant difference was found between two groups in predictor covariates or other clinically significant covariates after PSM, except for SPLC differentiation grade ([Table 3](#T3){ref-type="table"}). It should be noted that differentiation grade was considered a pathological variable and was best acquired from resected sample from surgery, which made the percentage of unknown differentiation grade significantly higher in the non-surgery group. We believed that the difference of differentiation grade of the two groups was mainly derived from surgery. Therefore, differentiation grade was not included as predictor covariates in PSM and did not compromise the comparison between the non-surgery group and the surgery group. Moreover, in the multivariate Cox regression, differentiation grade was not associated with any statistically significant survival difference.

###### 

Comparison of clinicopathological factors between the non-surgery group and surgery group after propensity score matching.

                                                                                                                                                                                                     **Non-surgery group**   **Surgery group**   ***P***           
  ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ----------------------- ------------------- --------- ------- --------
  Age                                                                                                                                                     ≤70 years old                              49                      60.5%               52        64.2%   0.63
                                                                                                                                                          \>70 years old                             32                      39.5%               29        35.8%   
  Gender                                                                                                                                                  Female                                     45                      55.6%               46        56.8%   0.87
                                                                                                                                                          Male                                       36                      44.4%               35        43.2%   
  Ethnicity[^@^](#TN9){ref-type="table-fn"}^,^[^\*^](#TN10){ref-type="table-fn"}                                                                          Caucasian                                  70                      86.4%               73        90.1%   0.5
                                                                                                                                                          African American                           9                       11.1%               5         6.2%    
                                                                                                                                                          Others                                     2                       2.5%                3         3.7%    
  Marital status at SPLC[^a^](#TN7){ref-type="table-fn"}                                                                                                  Married                                    39                      48.1%               42        51.9%   0.64
                                                                                                                                                          Not married                                42                      51.9%               39        48.1%   
  Interval between IPLC and SPLC                                                                                                                          ≤48 months                                 54                      66.7%               52        64.2%   0.74
                                                                                                                                                          \>48 months                                27                      33.3%               29        35.8%   
  SPLC laterality                                                                                                                                         Left                                       38                      46.9%               29        35.8%   0.15
                                                                                                                                                          Right                                      43                      53.1%               52        64.2%   
  Laterality relationship between SPLC and SCLC[^@^](#TN9){ref-type="table-fn"}^,^[^\*^](#TN10){ref-type="table-fn"}^,^[^b^](#TN8){ref-type="table-fn"}   Same                                       31                      38.3%               36        44.4%   0.33
                                                                                                                                                          Different                                  46                      56.8%               44        54.3%   
                                                                                                                                                          NA                                         4                       4.9%                1         1.2%    
  SPLC primary site[^@^](#TN9){ref-type="table-fn"}^,^[^\*^](#TN10){ref-type="table-fn"}                                                                  Upper lobe                                 58                      71.6%               48        59.3%   0.09
                                                                                                                                                          Middle lobe                                0                       0.0%                5         6.2%    
                                                                                                                                                          Lower lobe                                 22                      27.2%               27        33.3%   
                                                                                                                                                          Main bronchus/Overlapping lesion/Unknown   1                       1.2%                1         1.2%    
  SCLC primary site[^@^](#TN9){ref-type="table-fn"}^,^[^\*^](#TN10){ref-type="table-fn"}                                                                  Upper lobe                                 44                      54.3%               48        59.3%   0.80
                                                                                                                                                          Middle lobe                                2                       2.5%                2         2.5%    
                                                                                                                                                          Lower lobe                                 17                      21.0%               18        22.2%   
                                                                                                                                                          Main bronchus/Overlapping lesion/Unknown   18                      22.2%               13        16.0%   
  SPLC tumor size                                                                                                                                         ≤2 cm                                      49                      60.5%               43        53.1%   0.34
                                                                                                                                                          \>2 cm                                     32                      39.5%               38        46.9%   
  Lymph node involvement                                                                                                                                  No                                         75                      92.6%               76        93.8%   0.76
                                                                                                                                                          Yes                                        6                       7.4%                5         6.2%    
  SPLC stage                                                                                                                                              IA--IB                                     68                      84.0%               72        88.9%   0.36
                                                                                                                                                          IIA--IIIA                                  13                      16.0%               9         11.1%   
  SPLC histology[^\*^](#TN10){ref-type="table-fn"}                                                                                                        Adenocarcinoma                             29                      35.8%               26        32.1%   0.51
                                                                                                                                                          Squamous cell carcinoma                    36                      44.4%               43        53.1%   
                                                                                                                                                          Others                                     16                      19.8%               12        14.8%   
  SPLC differentiation grade[^\*^](#TN10){ref-type="table-fn"}                                                                                            Well/moderately differentiated             20                      24.7%               42        51.9%   \<0.01
                                                                                                                                                          Poorly differentiated/undifferentiated     23                      28.4%               30        37.0%   
                                                                                                                                                          unknown                                    38                      46.9%               9         11.1%   
  SCLC stage                                                                                                                                              Limited stage                              67                      82.7%               64        79.0%   0.55
                                                                                                                                                          Extensive stage                            14                      17.3%               17        21.0%   
  SCLC surgery                                                                                                                                            No                                         74                      91.4%               69        85.2%   0.22
                                                                                                                                                          Yes                                        7                       8.6%                12        14.8%   
  SCLC chemotherapy                                                                                                                                       No                                         9                       11.1%               11        13.6%   0.63
                                                                                                                                                          Yes                                        72                      88.9%               70        86.4%   
  SCLC radiotherapy                                                                                                                                       No                                         20                      24.7%               22        27.2%   0.72
                                                                                                                                                          Yes                                        61                      75.3%               59        72.8%   

SPLC, second primary non-small cell lung cancer after small cell lung cancer;

SCLC, small cell lung cancer;

At least one of the cells had expected cell count \<5, Fisher\'s exact test was used;

*Multiple comparisons were adjusted by Bonferroni correction*.

Notably, patients who underwent surgery demonstrated significantly improved survival both before (OS, 5-year rate: 41.2 vs. 11.6%, HR: 0.44, 95% CI: 0.32--0.61, *P* \< 0.01; CSS, 5-year rate: 46.8 vs. 24.3%, HR: 0.54, 95% CI: 0.38--0.77, *P* \< 0.01, [Figures 3A,B](#F3){ref-type="fig"}) and after PSM (OS, 5-year rate: 44.2 vs. 7.2%, HR: 0.48, 95% CI: 0.33--0.70, *P* \< 0.01; CSS, 5-year rate: 48.0 vs. 20.6%, HR: 0.44, 95% CI: 0.42--0.97, *P* = 0.03, [Figures 3C,D](#F3){ref-type="fig"}) compared to patients without surgery for SPLC.

![Survival analysis before and after propensity score matching (PSM): before PSM, overall survival **(A)** and lung cancer-specific survival **(B)** analysis; after PSM, overall survival **(C)** and lung cancer-specific survival **(D)** analysis. *P* value was calculated from log-rank test and pooled over strata, and the 95% confidence interval of the survival curves is depicted as a color band.](fonc-09-01552-g0003){#F3}

Discussion {#s4}
==========

Although the survival rate of SCLC remains dismal, certain number of patients survived long enough to develop second primary malignancies, including NSCLC ([@B4], [@B5]). However, the optimal management strategy for these patients remains unknown, and to the best of our knowledge, no previous study has evaluated the survival benefit of surgery in these patients. In this study, we utilized the SEER database to identify the largest cohort of early-stage SPLC after SCLC, and we found that surgery was associated with significantly better OS and CSS in these patients. To further confirm the survival benefits of surgery, we also conducted multivariate Cox regression, subgroup analysis, and PSM. As it turned out, surgery demonstrated consistent survival benefits in the multivariate Cox regression and most subgroups, indicating a wide range of application in early-stage SPLC after SCLC. Furthermore, surgery was also associated with better OS and CSS after PSM.

Not so many thoracic surgeons recommend surgery for early-stage SPLC after SCLC, especially after chemoradiation for the initial SCLC, as the dissection of pulmonary vessels can be challenging and technically demanding after definitive chemoradiation. Although studies on surgery after SCLC chemoradiation have been scarce, multiple studies have demonstrated that salvage surgery after failed Stereotactic Body Radiotherapy in early-stage NSCLC was safe and feasible and led to improved survival ([@B10]--[@B12]). A phase III randomized controlled trial also found that resection after induction chemoradiation was feasible and comparable to definitive chemoradiation in patients with locally advanced NSCLC ([@B13]). In our study, most patients received chemotherapy and radiotherapy for the initial SCLC. Similar to the studies described above, we believe that surgery for SPLC after SCLC can be safe, feasible, and beneficial in experienced hands.

The extent of resection and lymph node evaluation during surgery are two important aspects of NSCLC surgery. Previous studies have provided convincing evidence that recommended lobectomy over sublobar resection as standard of care for early-stage NSCLC ([@B14]--[@B16]), based on the associated longer survival and lower recurrence. On the other hand, the number of examined lymph node was also found to be an important prognostic factor ([@B17], [@B18]), and thorough lymph node evaluation may avoid downstaging. However, in our study, neither the extent of resection nor the number of examined lymph node was a prognostic factor within the surgery group. We believe that the decision on the extent of resection and lymph node evaluation should be individually based for patients with early-stage SPLC after SCLC. Multiple factors, including patients\' remaining pulmonary function, life expectancy, operative risk, and surgeon\'s experience should be considered. Moreover, further randomized controlled trials are needed to determine the optimal extent of resection and lymph node evaluation in patients with early-stage SPLC after SCLC.

Several limitations in our study are worth mentioning. First, several important variables are not available in SEER, including cardiopulmonary function, specific protocols of chemotherapy and radiotherapy, SCLC treatment response, and perioperative morbidity and mortality. Second, potential bias is inevitable due to the retrospective nature of this study. However, it should be noted that multivariate Cox regression and PSM were implemented to minimize this potential bias.

In conclusion, this population-based study has demonstrated that surgery is associated with significantly improved survival. Therefore, surgery should be considered in patients with early-stage SPLC after SCLC whenever possible. Nevertheless, further randomized controlled trials are warranted to confirm the safety and effect of surgery in these patients.
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